Bristol-Myers Squibb (NYSE:BMY) shares sold by OneAscent Financial Services LLC

OneAscent Financial Services LLC cut its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.2% in the first quarter, according to its most recent filing with the SEC. The fund owned 9,653 shares of the biopharmaceutical company’s stock after selling 321 shares during the period. OneAscent Financial Services LLC’s holdings in Bristol-Myers Squibb were worth $523,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb in the 4th quarter valued at $1,560,524,000. Primecap Management Co. CA lifted its position in shares of Bristol-Myers Squibb by 14.6% during the 4th quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company’s stock valued at $1,207,549,000 after purchasing an additional 2,998,228 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Bristol-Myers Squibb by 7.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 16,959,807 shares of the biopharmaceutical company’s stock, valued at $870,198,000 after purchased an additional 1,246,066 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Bristol-Myers Squibb by 1.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 11,361,717 shares of the biopharmaceutical company’s stock valued at $582,970,000 after purchasing an additional 134,815 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Bristol-Myers Squibb by 36.7% during the fourth quarter. Franklin Resources Inc. now owns 9,357,199 shares of the biopharmaceutical company’s stock valued at $480,118,000 after purchasing an additional 2,510,134 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s shares.

Bristol-Myers Squibb trading rose 0.0%

Shares of Bristol-Myers Squibb stock opened at $41.53 on Friday. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11, and a quick ratio of 0.99. The company has a market cap of $84.19 billion, a price-to-earnings ratio of -13.40, a PEG ratio of 14.20 and a beta of 0.43. Bristol-Myers Squibb has a one year low of $39.63 and a one year high of $65.38. The company’s fifty day moving average price is $42.97 and its two hundred day moving average price is $48.14.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, beating the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s quarterly revenue was up 4.7% year over year. In the same period last year, the company posted earnings of $2.05 per share. On average, analysts expect that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents an annualized dividend of $2.40 and a yield of 5.78%. The ex-dividend date is Friday, July 5. Bristol-Myers Squibb’s payout ratio is -77.42%.

Changes in Analyst Ratings

Several brokerages have issued reports on BMY. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. Barclays reduced their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Thursday. BMO Capital Markets reduced their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th . Finally, Societe Generale downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $60.00, according to MarketBeat.com.

Check out the latest stock analysis on Bristol-Myers Squibb

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured Articles

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.